Levetiracetam May Worsen Myoclonus in Patients With Juvenile Myoclonic Epilepsy

摘要: Levetiracetam was approved for generalized and partial epilepsy in pediatric adult population. It is also an effective antimyoclonus, but the evidence only supports its use as adjunctive agent along with other antiepileptic drugs, such sodium valproate, it commonly used cases juvenile myoclonic epilepsy. We report here 2 who were switched from valproate to levetiracetam avoid cosmetic or future teratogenic effect, this switch associated exaggerated myoclonus despite escalating dose of resolved completely after reintroducing valproate.